{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-090690","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.304483+00:00","generated_at":"2026-05-31T08:44:26.546177+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Apogee doses first healthy volunteers in Phase 1 trial of OX40L antibody APG990 for atopic dermatitis","bullets":["Initiated dosing in Phase 1 trial of APG990, a half-life extended OX40L antibody, enrolling ~40 healthy volunteers in 5 cohorts.","Interim safety and pharmacokinetic data from the Phase 1 trial expected in 2025.","Plans to start combination trial of APG777 (IL-13) and APG990 in 2025 for broader efficacy in atopic dermatitis.","CEO Michael Henderson: three programs advanced into clinical trials in 12 months since company's inception."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-090690","json":"https://secwatch.observer/filing/0001104659-24-090690.json","markdown":"https://secwatch.observer/filing/0001104659-24-090690.md","text":"https://secwatch.observer/filing/0001104659-24-090690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924090690/0001104659-24-090690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924090690/tm2421971d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:44:26.546177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}